Patents Examined by Robert S. Landsman
  • RNA molecules encoding cytokine fusion proteins and methods of use thereof
    Patent number: 10669322
    Abstract: The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms, pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 2, 2020
    Assignees: BIONTECH RNA PHARMACEUTICALS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GGMBH
    Inventors: Ugur Sahin, Friederike Gieseke, Sebastian Kreiter, Mustafa Diken
  • Fully human anti-C-X-C chemokine receptor 3 (CXCR3) antibodies and methods of use thereof
    Patent number: 10668148
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CXCR3 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR3, CXCR3-binding fragments and derivatives of such antibodies, and CXCR3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR3 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: June 2, 2020
    Assignee: Sorrento Therapeutics. inc.
    Inventors: Barbara A. Swanson, Dingqiu Huang, Heyue Zhou
  • In vitro methods of detecting heteroligomeric T1R2/T2R3-expressing cells that are potentially sensitive to sweet tastants
    Patent number: 10670584
    Abstract: The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners. Also the present invention relates to the use of hetero-oligomeric taste receptors comprising T1R1/T1R3 and T1R2/T1R3 in assays to identify compounds that respectively respond to umami taste stimuli and sweet taste stimuli. Further, the invention relates to the constitutive of cell lines that stably or transiently co-express a combination of T1R1 and T1R3; or T1R2 and T1R3; under constitutive or inducible conditions.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: June 2, 2020
    Assignee: Firmenich Incorporated
    Inventors: Mark Zoller, Xiaodong Li, Lena Staszewski, Shawn O'Connell, Sergey Zozulya, Jon Elliot Adler, Hong Xu, Fernando Echeverri
  • Method of identifying a status of a mucosal intestinal epithelial barrier to improve treatment of inflammatory bowel disease
    Patent number: 10663473
    Abstract: In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 26, 2020
    Assignee: Maximus Diagnostic Technologies LLC
    Inventor: Julia J. Liu
  • Method of treating vascular insulin resistance in a normoglycemic subject based on biomarkers
    Patent number: 10663462
    Abstract: The invention provides compositions and methods for determining insulin resistance and/or pancreatic ?-cell dysfunction in a subject. The invention also provides compositions and methods for treating a subject according to the insulin resistance and/or pancreatic ?-cell dysfunction in the subject.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: May 26, 2020
    Inventors: Andreas Pfuetzner, Thomas Forst
  • Antibodies which specifically bind ?Klotho polypeptide
    Patent number: 10663474
    Abstract: An antibody and/or binding fragment thereof, wherein the antibody and/or binding fragment thereof comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining region (CDR) CDR-L3 and the heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3, with the amino acid sequences of said CDRs comprising one or more of the sequences set forth below: CDR-L3; selected from any one of SEQ ID NOs: 123, 126-130, 142, 148 or 149; CDR-H1: SEQ ID NOs: 121 or 124; CDR-H2; SEQ ID NOs: 122 or 125; and/or CDR-H3: selected from any one of SEQ ID NOs: 196-226.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: May 26, 2020
    Assignees: The Governing Council of the University of Toronto, Board of Regents, The University of Texas System
    Inventors: Sachdev S. Sidhu, Sarah L. Barker, Orson W. Moe, Makoto Kuro-o, Johanne Pastor
  • Methods for delivering cargo into a cell by using signal molecules as cell penetration agents
    Patent number: 10654894
    Abstract: Novel cell penetrating agents for intracellular delivery of desired cargo, including proteins. Use of cell penetrating agents to deliver cargos to the interior of cells and cellular compartments and organelles is transformative for diagnostic, therapeutic, and research processes.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 19, 2020
    Assignee: KEENESAW STATE UNIVERSITY RESEARCH AND SERVICE FOUNDATION, INC.
    Inventors: Jonathan L. McMurry, John C. Salerno, Scott J. Nowak, Marcus C. Davis, Kathleen Bartlow
  • Method for treating prostatitis utilizing the pore-forming protein proaerolysin PRX302
    Patent number: 10654900
    Abstract: The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: May 19, 2020
    Assignee: Sophiris Bio, Corp.
    Inventor: J. Curtis Nickel
  • Nucleic acid molecules encoding antibodies to the human glucagon receptor
    Patent number: 10640566
    Abstract: The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 5, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Haruka Okamoto, Mark Sleeman, Joyce Harp
  • CD27 ligand (CD27L) single-chain fusion polypeptides
    Patent number: 10640543
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: May 5, 2020
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Biosensors for chloride ions
    Patent number: 10640766
    Abstract: This invention provides biosensors, cell models, and methods of their use for monitoring chloride ion, where the biosensors can include targeting domains, sensing domains and reporting domains. Biosensors can be introduced into cells reprogrammed to represent experimental or pathologic cells of interest, including as detectors of chloride ions, as TempoChloro™ accomplishes.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: May 5, 2020
    Assignee: TEMPO BIOSCIENCE, INC.
    Inventor: Angela Huang
  • Antibodies to connexin 43 (Cx43) hemichannels and methods of use thereof to inhibit Cx43 hemichannel opening
    Patent number: 10633442
    Abstract: Methods for identifying compounds that positively regulate connexin 43 hemichannels.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 28, 2020
    Assignee: Board of Regents of the University of Texas System
    Inventors: Jean X. Jiang, Manuel A. Riquelme, Sumin Gu
  • Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5
    Patent number: 10633425
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: April 28, 2020
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Laura D. J. Antipov, Shawdee Eshghi, Kristopher M. Kuchenbecker, Bjorn L. Millard, Matthew D. Onsum, Andrea D. Nickerson, Timothy R. Stowe, Yan Zhang
  • Methods of sensitizing a patient with glioma to a therapeutic agent by administering small hairpin RNA targeting PDZ-RHOGEF
    Patent number: 10624895
    Abstract: The technology encompasses methods of treating a patient with cancer, such as glioblastoma. The methods may include the administration of one or more pharmaceutical compositions that are capable of inhibiting TROY to treat the patient with cancer.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 21, 2020
    Assignees: The Translational Genomics Research Institute, Mayo Foundation for Medical Education and Research
    Inventors: Nhan Tran, Joseph C. Loftus, Harshil Dhruv
  • Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
    Patent number: 10626399
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: April 21, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
  • Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
    Patent number: 10626180
    Abstract: The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: April 21, 2020
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dermot McGovern, Stephan Targan, Dalin Li
  • Sublingual fentanyl spray
    Patent number: 10610523
    Abstract: The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: April 7, 2020
    Assignee: BTCP PHARMA, LLC
    Inventors: S. George Kottayil, Venkat R. Goskonda, Zhongyuan Zhu, Linet Kattookaran, Neha Parikh
  • Methods for treating or reducing liver diseases by administering oral composition comprising TNF receptor fusion proteins
    Patent number: 10611821
    Abstract: This application describes a method of delivering a TNF antagonist molecule, in a biologically active form, to a subject in need thereof, the method comprising, orally or mucosally administering to the subject a therapeutically effective amount of a TNF antagonist molecule. This application further describes a method of treating, preventing or reducing liver diseases, the method comprising, administering to the subject a therapeutically effective amount of a TNF antagonist molecule.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: April 7, 2020
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventor: Yaron Ilan
  • Humanized monoclonal antibodies that target protein tyrosine phosphatase-beta (HPTP-?/VE-PTP)
    Patent number: 10604569
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 31, 2020
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Michael Allen Flynn
  • Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
    Patent number: 10604740
    Abstract: A nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of a human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain that are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (EGFR) for specific recognition of 287th to 302nd amino acid epitopes of a human epidermal growth factor receptor (EGFR).
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: March 31, 2020
    Assignee: CarsGEN Therapeutics Limited
    Inventors: Zonghai Li, Huiping Gao, Hua Jiang, Bizhi Shi